Unraveling the molecular and epigenetic pathways that govern HIF-1α expression in T cell regulation under inflammatory and tumor-promoting conditions is essential to develop targeted therapies to interrupt the signaling pathways towards hypoxia-induced inflammation promoting tumor progression or manifestation of autoimmunity. Here, HIF1A is linked to neoplasm.